The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Open accessAbstract
BACKGROUND: Depression is the predominant pole of illness disability in bipolar disorder and, compared with acute mania, has less systematic research guiding treatment development. The aim of this review is to present the therapeutic options currently available for managing bipolar depression and to highlight areas of unmet need and future research. METHODS: Literature search of PubMed, PsycINFO, and Cochrane databases and bibliographies from 2000 to August 2013 for treatments that have regulatory approval for bipolar depression or early controlled preliminary data on efficacy. RESULTS: Treatment options for bipolar depression have increased over the last decade, most notably with regulatory approval for olanzapine/fluoxetine combination, quetiapine, and lurasidone. Conventional mood stabilizers lamotrigine and divalproex have meta-analyses suggesting acute antidepressant response. Manual-based psychotherapies also appear to be effective in treating bipolar depression. The therapeutic utility of unimodal antidepressants, as a class, for the treatment of patients with bipolar depression, as a group, remains to be confirmed. There is a substantially unmet need to develop new interventions that are efficacious, effective, and have low side effect burden. LIMITATIONS: Additional compounds are currently being developed that may ultimately be applicable to the treatment of bipolar depression and early open-trial data encourage further studies, but both of these topics are beyond the scope of this review. CONCLUSION: Future registrational trials will need to establish initial efficacy, but increasing interest for personalized or individualized medicine will encourage further studies on individual predictors or biomarkers of response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, additional evidence-based treatment options for bipolar depression is a recognized unmet need. 8”
From Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials (2020) · cites this paper as [8]
Citations
Cites
Yatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Cuthbert, B. N., & Insel, T. R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-126 · Cited by 3,053
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression
Goodwin, F. K., & Jamison, K. R. (2007) · Medical Entomology and Zoology · Cited by 1,325
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937
The inventory for depressive symptomatology (IDS): Preliminary findings
John Rush, A., Giles, D. E., Schlesser, M. A., Fulton, C. L., Weissenburger, J., & Burns, C. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90060-0 · Cited by 918
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
Research works printed but not linked: 2
- Frye, 2013, Efficacy and safety of armodafinil as an adjunctive therapy for the treatment of a major depressive episode associated with bipolar I disorder, Bipolar Disord., 15, 126
- Tye, 2013, Allostatic overload: transcriptomic insights into the molecular basis of antidepressant resistance, Bipolar Disord., 15, 41
Cited by
Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders
Forte, A., Baldessarini, R. J., Tondo, L., Vázquez, G. H., Pompili, M., & Girardi, P. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.02.011 · Cited by 203
“Individualized and critically targeted interventions are more likely to be provided in specialized mood-disorder clinics or centers, accessibility to which should be enhanced and their methods made more widely available (Crowe et al., 2011; Frye et al., 2014; Vieta, 2013).”
BackgroundOstacher, M., Ng-Mak, D., Patel, P., Ntais, D., Schlueter, M., & Loebel, A. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285050 · Cited by 202
A History of the Pharmacological Treatment of Bipolar Disorder
Lopez-Munoz, F. J., Shen, W., D’Ocón, P., Romero, A., & Álamo, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072143 · Cited by 168
Bobo, W. V., Voort, J. L. V., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 126
Self-citationInnovative approaches to bipolar disorder and its treatment
Harrison, P. J., Cipriani, A., Harmer, C. J., Nobre, A. C., Saunders, K., Goodwin, G. M., & Geddes, J. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13048 · Cited by 137
Metadata
- Authors
- Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J.
- Affiliations
- Mayo Clinic (US)
- Universidad de Los Andes, Chile (CL)
- Corresponding author
- Frye, Mark A.
- ORCID
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 169
- Pages
- S17-S23
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2114940817
- Cited by
- 36
- References
- 87
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 5
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 29 d)
- Locations
- Journal of Affective Disorders (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Universidad Peruana Cayetano Heredia Institutional Repository (publishedVersion)
- Funders
- Teva Pharmaceutical Industries
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Keywords
- bipolar depression, bipolar disorder, antidepressant treatment, unmet treatment needs, olanzapine-fluoxetine combination, quetiapine, lurasidone, lamotrigine, divalproex, mood stabilizers, personalized medicine, treatment response biomarkers
- MeSH terms
- Lurasidone Hydrochloride, Quetiapine Fumarate, Lamotrigine, Anticonvulsants, Antidepressive Agents, Benzodiazepines, Bipolar Disorder, Dibenzothiazepines, Drug Combinations, Fluoxetine, Forecasting, Health Services Needs and Demand, Humans, Psychotherapy, Thiazoles, Triazines, Isoindoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current landscape, unmet needs, and future directions for treatment of bipolar depression. https://app.cochat.ai/papers/10.1016/s0165-0327(14)70005-9
- The paper
- Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014). Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(14)70005-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.